Our capabilities in pharmaceuticals

Acne vulgaris is a chronic inflammatory skin disease, most prevalent in adolescents and young adults, often requiring individualised management over many years.

Estimated to affect up to 85% of adolescents and young adults worldwide, with a global burden of over 650 million people affected.

Beyond physical symptoms, acne has well-documented psychosocial effects, influencing quality of life, self-esteem, and long-term skin health.

(In the pipeline - Phase 3)

The most common form of hair loss among men, characterized by progressive thinning in a defined pattern.

Affects approximately 30–50% of men by the age of 50 globally, with prevalence over 40% in some countries.

Early onset can have significant psychosocial consequences, motivating ongoing research toward novel interventions.

Ulcerative colitis, a form of inflammatory bowel disease (IBD) characterized by chronic inflammation of the colon.

Affects 9–20 per 100,000 globally, with higher rates in North America and Europe; rising incidence in newly industrialized countries.

Leads to symptoms such as abdominal pain, diarrhea, rectal bleeding, and can significantly reduce patient quality of life.

In the pipeline (Phase 2):

Targeted treatments (in development) for inflammation limited to the distal colon/rectum.

Represents a subset of UC, requiring local/topical therapy approaches for optimal outcomes.

Proctitis and left-sided disease are significant causes of symptoms and healthcare utilization in UC patients.

Induction of remission in mild to moderate ulcerative colitis; also used in microscopic colitis management.

IBD (including UC and Crohn’s) affects more than 6.8 million globally.

Chronic disease requiring long-term management to prevent flares and complications; substantial healthcare and societal burden.

In the pipeline (Phase 2):

Novel therapies in clinical development for diagnosis and management of bile acid diarrhea (BAD).

BAD affects ~1% of the population, especially those with IBS-D.

Persistent diarrhea, bloating, and abdominal pain can severely impair daily activities; often underdiagnosed.

Diagnostic aid for visualization during colonoscopy (chromoendoscopy for detection of colonic lesions).

Prevalence of colorectal cancer: Third most common cancer worldwide, with >1.9 million new cases annually. Early detection via colonoscopy is a key public health priority.

Enhanced visualization improves polyp detection rates, which directly correlates to colorectal cancer prevention.

Treatment of traveler’s diarrhea caused by non-invasive strains of Escherichia coli; may also be explored for IBS-D.

Traveler’s diarrhea affects up to 40% of travelers to high-risk regions. Chronic diarrhea is a common and challenging presentation in GI clinics.

Leads to significant morbidity, time lost from work/travel, and in certain populations, risk of dehydration and further complications.

Short-acting intravenous sedation for procedures such as endoscopy.

Over 20 million GI endoscopy procedures performed each year in the US alone, with similar trends globally.

Safe, effective sedation is crucial for high-quality, patient-friendly procedural care.